Amgen Wraps Up Pediatric Psoriasis Trial in Japan, Paving Way for Otezla Growth

Amgen has completed a Phase 3 study of apremilast, also known as Otezla, in Japanese children and teens with moderate to severe plaque psoriasis. The trial involved administering the oral tablet to patients aged 6-17 years old.

The goal of the study was to assess the efficacy and safety of apremilast for this age group, which is a key step towards expanding its use in pediatric patients.

As part of the study's design, all enrolled patients received apremilast without any comparison drug. This open-label trial aimed to test real-world benefit and safety in routine use.

The study was first submitted on September 20, 2022, and the latest update was posted on September 30, 2026, marking its completion.